Cited by 1,490Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Open access

Herbst, Roy S., Prager, Diane, Hermann, Robert, Fehrenbacher, Lou, Johnson, Bruce E., Sandler, Alan, Kris, Mark G., Tran, Hai T., Klein, Pam, Li, Xin, Ramies, David, Johnson, David H., Miller, Vincent A.·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.02.840

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with non-small-cell lung cancer (NSCLC). Erlotinib was combined with chemotherapy to determine if it could improve the outcome of patients with NSCLC. PATIENTS AND METHODS: TRIBUTE randomly assigned patients with good performance status and previously untreated advanced (stage IIIB/IV) NSCLC to erlotinib 150 mg/d or placebo combined with up to six cycles of carboplatin and paclitaxel, followed by maintenance monotherapy with erlotinib. Random assignment was stratified by stage, weight loss in the previous 6 months, measurable disease, and treatment center. The primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response (OR), and duration of response. RESULTS: There were 1,059 assessable patients (526 erlotinib; 533 placebo). Median survival for patients treated with erlotinib was 10.6 v 10.5 months for placebo (hazard ratio, 0.99; 95% CI, 0.86 to 1.16; P = .95). There was no difference in OR or median TTP. Patients who reported never smoking (72 erlotinib; 44 placebo) experienced improved OS in the erlotinib arm (22.5 v 10.1 months for placebo), though no other prespecified factors showed an advantage in OS with erlotinib. Erlotinib and placebo arms were equivalent in adverse events (except rash and diarrhea). CONCLUSION: Erlotinib with concurrent carboplatin and paclitaxel did not confer a survival advantage over carboplatin and paclitaxel alone in patients with previously untreated advanced NSCLC. Never smokers treated with erlotinib and chemotherapy seemed to experience an improvement in survival and will undergo further investigation in future randomized trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.02.840

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Cancer burden in the year 2000. The global picture
Parkin, D. M., Bray, F. I., & Devesa, S. S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00267-2 · Cited by 2,169
DECLARATION OF HELSINKI.
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069

Flagged first, then by citations

Show all 25 references

Sorted by citations

Items 201–300 of 1,000

Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
Pennell, N. A., & Lynch, T. J. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0276 · Cited by 100
The Impact of EGFR Mutation Status on Outcomes in Patients With Resected Stage I Non-Small Cell Lung Cancers
Izar, B., Sequist, L. V. D., Lee, M., Muzikansky, A., Heist, R. S., Iafrate, J., Dias-Santagata, D. C., Mathisen, D. J., & Lanuti, M. D. (2013) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2013.05.091 · Cited by 101
EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
Ke, E., & Wu, Y.-L. L. C. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.09.003 · Cited by 101
Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non–small cell lung cancer cells
Schaeybroeck, S. V., Kyula, J., Kelly, D. M., Karaı̈skou, A., Stokesberry, S. A., Cutsem, E. V., Longley, D. B., & Johnston, P. G. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0446 · Cited by 100
Src as a potential therapeutic target in non-small-cell lung cancer
Giaccone, G., & Zucali, P. A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn048 · Cited by 99
Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib
Clark, G. M., Zborowski, D. M., Culbertson, J. L., Whitehead, M., Savoie, M., Seymour, L., & Shepherd, F. A. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30414-7 · Cited by 98
Erlotinib: Small-molecule targeted therapy in the treatmentof non-small-cell lung cancer
Smith, J. A. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.10.014 · Cited by 98
Pulmonary toxicities from targeted therapies: a review
Barber, N. A., & Ganti, A. K. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0199-0 · Cited by 97
Positron Emission Tomography and Improved Survival in Patients With Lung Cancer The Will Rogers Phenomenon Revisited
Chee, K. G. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.14.1541 · Cited by 97
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
Uramoto, H., & Mitsudomi, T. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603665 · Cited by 97
Resistance to epidermal growth factor receptor-targeted therapy
Morgillo, F., & Lee, H. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.08.004 · Cited by 96
Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight
Min, J. H., Lee, H. Y., Lim, H.-Y., Ahn, M., Park, K., Chung, M. P., & Lee, K. S. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1737-2 · Cited by 99
A review of erlotinib and its clinical use
Tang, P. A., Tsao, M., & Moore, M. J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.2.177 · Cited by 96
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Azzoli, C. G., Giaccone, G., & Temin, S. (2010) · Journal of Oncology Practice · doi:10.1200/jop.091065 · Cited by 96
Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy
Friess, T., Scheuer, W., & Hasmann, M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2642 · Cited by 95
Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review
Borkar, D. S., Lacouture, M. E., & Basti, S. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-012-1645-y · Cited by 96
The biology, function and clinical implications of exosomes in lung cancer
Zhou, L. Q., Lv, T., Zhang, Q., Zhu, Q., Zhan, P., Zhu, S., Zhang, J., & Song, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.003 · Cited by 92
Combining Targeted Therapies and Drugs with Multiple Targets in the Treatment of NSCLC
Maione, P., Gridelli, C., Troiani, T., & Ciardiello, F. (2006) · The Oncologist · doi:10.1634/theoncologist.11-3-274 · Cited by 92
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104
Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer
Laurie, S. A., & Goss, G. D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4522 · Cited by 93
Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status
Kalikaki, A., Koutsopoulos, A. V., Hatzidaki, D., Trypaki, M., Kontopodis, E., Stathopoulos, E. N., Mavroudis, D., Georgoulias, V., & Voutsina, A. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.09.010 · Cited by 91
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Joerger, M., von Pawel, J., Kraff, S., Fischer, J. R., Eberhardt, W., Gauler, T. C., Mueller, L., Reinmuth, N., Reck, M., Kimmich, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw290 · Cited by 91
Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway
Rosell, R., Tarón, M., Reguart, N., Isla, D., & Morán, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0627 · Cited by 92
Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy
Li, X., Liu, J.-T., Fan, L.-L., Liu, Y., Cheng, L., Wang, F., Yu, H., Gao, J., Wei, W., Wang, H., et al. (2016) · OncoTarget · doi:10.18632/oncotarget.8358 · Cited by 76
EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Cappuzzo, F., Ligorio, C., Toschi, L., Rossi, E., Trisolini, R., Paioli, D., Magrini, E., Finocchiaro, G., Bartolini, S., Cancellieri, A., et al. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000268676.79872.9b · Cited by 89
Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer
Yoshida, T., Zhang, G., & Haura, E. B. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.05.014 · Cited by 92
Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals
Ling, J., Fettner, S. H., Lum, B. L., Riek, M., & Rakhit, A. K. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f2d8e4 · Cited by 89
Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer
Heymach, J. V., Nilsson, M. B., Blumenschein, G., Papadimitrakopoulou, V. A., & Herbst, R. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0286 · Cited by 88
ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development
Scagliotti, G. V., Stahel, R. A., Rosell, R., Thatcher, N., & Soria, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.001 · Cited by 90
Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer
Hanrahan, E. O., Ryan, A. J., Mann, H., Kennedy, S. J., Langmuir, P. B., Natale, R. B., Herbst, R. S., Johnson, B. E., & Heymach, J. V. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2568 · Cited by 88
Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
Goffin, J. R., & Zbuk, K. M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.08.007 · Cited by 88
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade
Wu, W., Onn, A., Isobe, T., Itasaka, S., Langley, R. R., Shitani, T., Shibuya, K., Komaki, R. U., Ryan, A. J., Fidler, I. J., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0416 · Cited by 88
Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature
Zhou, C., & Yao, L. D. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.002 · Cited by 87
High-Dose Cytarabine (HD araC) in the Treatment of Leukemias: a Review
Reese, N., & Schiller, G. J. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0156-3 · Cited by 87
Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies.
Simone, C. B., Burri, S. H., & Heinzerling, J. H. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.10.05 · Cited by 85
Non-Small-Cell Lung Cancer: Treatment of Late Stage Disease: Chemotherapeutics and New Frontiers
Scheff, R. J., & Schneider, B. J. (2013) · Seminars in Interventional Radiology · doi:10.1055/s-0033-1342961 · Cited by 88
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer
Gross, M. E., Higano, C. S., Pantuck, A. J., Castellanos, O. O., Green, E., NGUYEN, K. N., & Agus, D. B. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-142 · Cited by 85
Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model
Chao, P., Deshmukh, M., Kutscher, H. L., Gao, D., Rajan, S. S., Hu, P., Laskin, D. L., Stein, S., & Sinko, P. J. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328332a322 · Cited by 84
Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice
Jacoby, J. J., Erez, B., Korshunova, M. V., Williams, R. R., Furutani, K., Takahashi, O., Kirkpatrick, L., Lippman, S. M., Powis, G., O'Reilly, M. S., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181dc211f · Cited by 84
“All seven mice that were killed before the end of the experiment had metastatic disease, some in multiple organs, including the lymph nodes (four mice), bone (3), brain (2), and liver (1).”
Background
Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non—Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments
Rossi, G., Pelosi, G., Graziano, P., Barbareschi, M., & Papotti, M. G. (2009) · International Journal of Surgical Pathology · doi:10.1177/1066896909336178 · Cited by 84
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
Hsu, Y.-F., Ajona, D., Corrales, L. P., López-Picazo, J. M., Gúrpide, A., Montuenga, L. M., & Pı́o, R. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-139 · Cited by 84
Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
Cadranel, J. L., Ruppert, A.-M., Beau‐Faller, M., & Wislez, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.009 · Cited by 83
Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
Domvri, K., Zarogoulidis, P., Darwiche, K., Browning, R. F., Jr., Li, Q., Turner, J. F., Kioumis, I. P., Spyratos, D., Porpodis, Κ., Papaiwannou, A., et al. (2013) · Journal of Cancer · doi:10.7150/jca.7734 · Cited by 82
Impact of Environmental Tobacco Smoke on the Incidence of Mutations in Epidermal Growth Factor Receptor Gene in Never-Smoker Patients With Non–Small-Cell Lung Cancer
Lee, Y. J., Cho, B. C., Jee, S. H., Moon, J. W., Kim, S. I., Chang, J., Chung, K. S., Park, I. K., Choi, S. H., & Kim, J.-H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.5480 · Cited by 82
Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape
Pal, S. K., Figlin, R. A., & Reckamp, K. L. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0239 · Cited by 81
Epidermal Growth Factor ReceptorMutation Testing in the Care of Lung Cancer Patients
Sequist, L. V. D., Joshi, V. A., Janne, P. A., Bell, D. W., Fidias, P. M., Lindeman, N. I., Louis, D. N., Lee, J. C., Mark, E. J., Longtine, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0099 · Cited by 81
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
Rolfo, C. D., Giovannetti, E., Hong, D. S., Bivona, T. G., Raez, L. E., Bronte, G., Buffoni, L., Reguart, N., Santos, E. S., Germonpré, P. R., et al. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.009 · Cited by 80
Novel therapeutic targets in non-small cell lung cancer
Alamgeer, M., Ganju, V., & Watkins, D. N. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.03.010 · Cited by 84
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives
Rebuzzi, S. E., Alfieri, R. R., Monica, S. L., Minari, R., Petronini, P. G., & Tiseo, M. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102820 · Cited by 80
Targeted therapies in bladder cancer—an update
Black, P. C., Agarwal, P. K., & Dinney, C. P. (2007) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.05.011 · Cited by 80
A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer
Hirsch, F. R., Kabbinavar, F. F., Eisen, T. G., Martins, R. G., Schnell, F. M., Dziadziuszko, R., Richardson, K., Richardson, F. C., Wacker, B., Sternberg, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4929 · Cited by 79
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
Chen, M. C., Chen, C. H., Wang, J.-C., Tsai, A.-C., Liou, J.-P., Pan, S.-L., & Teng, C.-M. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.330 · Cited by 80
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta‐analysis of clinical trials
Qi, W., Shen, Z., Lin, F., Sun, Y., Min, D., Tang, L., He, A., & Yao, Y. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04417.x · Cited by 79
Management of egfr tki—Induced Dermatologic Adverse Events
Melosky, B. L., Leighl, N. B., Rothenstein, J. M., Sangha, R. S., Stewart, D. J., & Papp, K. A. (2015) · Current Oncology · doi:10.3747/co.22.2430 · Cited by 78
MicroRNA-574-5p promotes metastasis of non-small cell lung cancer by targeting PTPRU
Zhou, R., Zhou, X., Yin, Z., Guo, J., Hu, T., Jiang, S., Liu, L., Dong, X., Zhang, S., & Wu, G. (2016) · Scientific Reports · doi:10.1038/srep35714 · Cited by 78
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations
Sakurada, A., Shepherd, F. A., & Tsao, M. (2006) · Clinical Lung Cancer · doi:10.3816/clc.2006.s.005 · Cited by 78
Targeted therapies in the treatment of advanced/metastatic NSCLC
Pallis, A. G., Serfass, L., Dziadziuszko, R., van Meerbeeck, J. P., Fennell, D. A., Lacombe, D., Welch, J., & Gridelli, C. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.06.005 · Cited by 78
Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer
Lee, K. H., Lee, J. S., Kim, S., Pereira, J. R., Han, B., Song, X., Wang, J., Kim, H.-K., Sahoo, T. P., Digumarti, R., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.035 · Cited by 79
MicroRNA-1253 suppresses cell proliferation and invasion of non-small-cell lung carcinoma by targeting WNT5A
Liu, M., Zhang, Y., Zhang, J., Cai, H., Zhang, C., Yang, Z., Niu, Y., Wang, H., Wei, X., Wang, W., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0218-x · Cited by 77
Schedule-Dependent Apoptosis in K-ras Mutant Non–Small-Cell Lung Cancer Cell Lines Treated with Docetaxel and Erlotinib: Rationale for Pharmacodynamic Separation
Mahaffey, C. M., Davies, A. M., Lara, P. N., Pryde, B. J., Holland, W. S., Mack, P. C., Gumerlock, P. H., & Gandara, D. R. (2007) · Clinical Lung Cancer · doi:10.3816/clc.2007.n.041 · Cited by 77
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
Bronte, G., Rolfo, C. D., Giovannetti, E., Cicero, G., Pauwels, P., Passiglia, F., Castiglia, M., Rizzo, S., Vullo, F. L., Fiorentino, E., et al. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.003 · Cited by 78
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials
Qi, W., Sun, Y., Shen, Z., & Yao, Y. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000189 · Cited by 76
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR- Activating Mutation
Monica, S. L., Madeddu, D., Tiseo, M., Vivo, V., Galetti, M., Cretella, D., Bonelli, M. A., Fumarola, C., Cavazzoni, A., Falco, A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.006 · Cited by 75
Substrate‐dependent bidirectional modulation of P‐glycoprotein‐mediated drug resistance by erlotinib
Noguchi, K., Kawahara, H., Kaji, A., Katayama, K., Mitsuhashi, J., & Sugimoto, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01213.x · Cited by 75
Effect of Disrupting Seven-in-Absentia Homolog 2 Function on Lung Cancer Cell Growth
Ahmed, A. U., Schmidt, R. L., Park, C. H., Reed, N. R., Hesse, S. E., Thomas, C. F., Molina, J. R., Deschamps, C. C., Yang, P., Aubry, M. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn365 · Cited by 76
Targeting mTOR signaling in lung cancer
Marinov, M., Fischer, B. E., & Arcaro, A. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.04.002 · Cited by 74
Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency
Hu, S., Fu, W., Li, T., Yuan, Q., Wang, F., Lv, G., Lv, Y., Fan, X., Shen, Y., Lin, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0339 · Cited by 72
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study
Herbst, R. S., Redman, M. W., Kim, E. S., Semrad, T. J., Bazhenova, L. A., Masters, G. A., Oettel, K. R., Guaglianone, P. P., Reynolds, C., Karnad, A. B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30694-0 · Cited by 73
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
Greenhalgh, J., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Chaplin, M., & Green, J. A. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010383.pub3 · Cited by 73
Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy
Cserepes, M., Ostoros, G., Lohinai, Z., Rásó, E., Barbai, T., Tı́már, J., Rózsás, A., Moldvay, J., Kovalszky, I., Fábián, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.001 · Cited by 75
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
Morgillo, F., Bareschino, M. A., Bianco, R., Tortora, G., & Ciardiello, F. (2007) · Differentiation · doi:10.1111/j.1432-0436.2007.00200.x · Cited by 75
Predicting the outcome of chemotherapy for lung cancer
Rosell, R., Cecere, F. L., Santarpía, M., Reguart, N., & Tarón, M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.01.011 · Cited by 73
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib ofEGFRmutant advanced lung adenocarcinoma
Bria, E., Pilotto, S., Amato, E., Fassan, M., Novello, S., Peretti, U., Vavalà, T., Kinspergher, S., Righi, L., Santo, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3727 · Cited by 74
Epidermal growth factor receptor immunohistochemistry
Hirsch, F. R., Dziadziuszko, R., Thatcher, N., Mann, H., Watkins, C. L., Parums, D. V., Speake, G., Holloway, B. R., Bunn, P. A., & Franklin, W. A. (2008) · Cancer · doi:10.1002/cncr.23282 · Cited by 72
Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
Klein, R. W., Wielage, R. C., Muehlenbein, C. E., Liepa, A. M., Babineaux, S. M., Lawson, A., & Schwartzberg, L. S. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e15d16 · Cited by 71
Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer
Choong, N. W., Mauer, A. M., Haraf, D. J., Lester, E. P., Hoffman, P. C., Kozloff, M. F., Lin, S., Dancey, J. E., Szeto, L. L., Grushko, T. A., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818396a4 · Cited by 70
Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment
Schettino, C., Bareschino, M. A., Ricci, V., & Ciardiello, F. (2008) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2.2.167 · Cited by 70
Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines
Pino, M. S., Balsamo, M., Modugno, F. D., Mottolese, M., Alessio, M., Melucci, E., Milella, M., McConkey, D. J., Philippar, U., Gertler, F. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0436 · Cited by 70
EGFR inhibition in the treatment of non‐small cell lung cancer
Gerber, D. E. (2008) · Drug Development Research · doi:10.1002/ddr.20268 · Cited by 70
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
Gridelli, C., Ardizzoni, A., Douillard, J., Hanna, N. H., Manegold, C., Perrone, F., Pirker, R., Rosell, R., Shepherd, F. A., Petris, L. D., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.11.018 · Cited by 70
Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib, Erlotinib, Afatinib, Dacomitinib, and Icotinib in the Treatment of Non-Small-Cell Lung Cancer: A Systematic Review
Ellis, P. M., Coakley, N., Feld, R. D., Kuruvilla, S., & Ung, Y. (2015) · Current Oncology · doi:10.3747/co.22.2566 · Cited by 71
Enzastaurin, an Oral Serine/Threonine Kinase Inhibitor, As Second- or Third-Line Therapy of Non–Small-Cell Lung Cancer
Oh, Y. W., Herbst, R. S., Burris, H. A., Cleverly, A., Musib, L. C., Lahn, M., & Bepler, G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3685 · Cited by 69
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Plus Chemotherapy: Case Closed or Is the Jury Still Out?
Gandara, D. R., & Gumerlock, P. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.030 · Cited by 69
Gefitinib for advanced non-small cell lung cancer
Sim, E., Yang, I. A., Wood-Baker, R. R., Bowman, R., & Fong, K. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006847.pub2 · Cited by 71
ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis
Sebille, Y. Z. A. V., Gibson, R. J., Wardill, H. R., & Bowen, J. M. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.011 · Cited by 68
Liquid Biopsy: From Basic Research to Clinical Practice
Macías, M., Alegre, E., Díaz‐Lagares, Á., Patiño‐García, A., Perez‐Gracia, J. L., Sanmamed, M. F., López‐López, R., Varo, N., & González, Á. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2017.10.003 · Cited by 71
Accelerating anticancer drug development — opportunities and trade-offs
Nass, S. J., Rothenberg, M. L., Pentz, R. D., Hricak, H., Abernethy, A. P., Anderson, K. C., Gee, A. W., Harvey, R. D., Piantadosi, S., Bertagnolli, M. M., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0102-3 · Cited by 70
The “Lazarus Response” in Treatment-Naïve, Poor Performance Status Patients With Non–Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation
Langer, C. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4859 · Cited by 68
In-Depth Analysis Shows Synergy between Erlotinib and miR-34a
Zhao, J. Y., Kelnar, K., & Bader, A. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089105 · Cited by 67
Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Study S0342
Herbst, R. S., Kelly, K. L., Chansky, K., Mack, P. C., Franklin, W. A., Hirsch, F. R., Atkins, J. N., Dakhil, S. R., Albain, K. S., Kim, E. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9356 · Cited by 68
First- and second-line therapy for advanced nonsmall cell lung cancer
Jp, S., & Moro‐Sibilot, D. (2009) · European Respiratory Journal · doi:10.1183/09031936.00132008 · Cited by 67
Presentation and Stage-Specific Outcomes of Lifelong Never-smokers with Non-small Cell Lung Cancer (NSCLC)
Subramanian, J., Velcheti, V., Gao, F., & Govindan, R. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318145af79 · Cited by 67
Impact of Smoking Status on EGFR-TKI Efficacy for Advanced Non–Small-Cell Lung Cancer in EGFR Mutants: A Meta-analysis
Zhang, Y., Kang, S., Fang, W., Hong, S., Liang, W., Yan, Y., Qin, T., Tang, Y., Jin, S., & Zhang, L. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.09.008 · Cited by 66
Recent advances of novel targeted therapy in non-small cell lung cancer
Katzel, J. A., Fanucchi, M. P., & Li, Z. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-2 · Cited by 70
Phase I Study of Concurrent Whole Brain Radiotherapy and Erlotinib for Multiple Brain Metastases From Non–Small-Cell Lung Cancer
Lind, J. S. W., Lagerwaard, F. J., Smit, E. F., & Senan, S. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.026 · Cited by 67
The current status of targeted therapy for non‐small cell lung cancer
Francis, H., & Solomon, B. (2009) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.02141.x · Cited by 66
Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503
Amann, J. M., Lee, J., Röder, H., Brahmer, J. R., González, A., Schiller, J. H., & Carbone, D. P. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c8cbd9 · Cited by 66
EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer
Mack, P. C., Holland, W. S., Burich, R. A., Sangha, R. S., Solis, L. J., Li, Y., Beckett, L. A., Lara, P. N., Davies, A. M., & Gandara, D. R. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181bbf239 · Cited by 65
EGFR and K-ras Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors
Sartori, G., Cavazza, A., Sgambato, A., Marchioni, A., Barbieri, F., Longo, L., Bavieri, M., Murer, B., Meschiari, E., Tamberi, S., et al. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcph0trmpxvzw2f · Cited by 66
Prognostic and predictive factors for lung cancer
Paesmans, M. (2012) · Breathe · doi:10.1183/20734735.006911 · Cited by 71

Authors: Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., Ramies, D., Johnson, D. H., & Miller, V. A.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
ORCID: Herbst, Roy S.
Johnson, Bruce E.
Sandler, Alan
Kris, Mark G.
Tran, Hai T.
Li, Xin
Ramies, David
Johnson, David H.
Miller, Vincent A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-09-01
Volume: 23
Issue: 25
Pages: 5892-5899
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.02.840
OpenAlex: W2162724777
Cited by: 1,490
References: 25
Citations by year: 2026: 9 · 2025: 4 · 2024: 7 · 2023: 11 · 2022: 19 · 2021: 24 · 2020: 29 · 2019: 22 · 2018: 32 · 2017: 48 · 2016: 56 · 2015: 83 · 2014: 79 · 2013: 122 · 2012: 96
FWCI: 123.05
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: erlotinib, carboplatin, paclitaxel, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, combination chemotherapy, never smokers, overall survival, time to progression, objective response, maintenance therapy
MeSH terms: Erlotinib Hydrochloride, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Placebos, Quinazolines, Survival Analysis, Carboplatin, Paclitaxel, Disease Progression, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks